Drugs and Chemicals of
Concern > 2,5-Dimethoxy-4-(n)-propylthiophenethylamine
(2C-T-7)
2,5-DIMETHOXY-4-(n)-PROPYLTHIOPHENETHYLAMINE
(Street Names: 2C-T-7, Blue Mystic, T7, Beautiful, Tripstay,
Tweety-Bird Mescaline)
August 2007
DEA/OD/ODE
I ntroduction:
In the fall of 2000, a
young healthy male died following snorting an excessive amount
of 2C-T-7. Since this initial 2C-T-7-related death, two
additional deaths reported in April 2001 have been linked to
2C-T-7. These two deaths resulted from the co-abuse of 2C-T-7
with MDMA.
Licit Uses:
2C-T-7 is not approved for
marketing by the Food and Drug Administration and is not sold
legally in the United States.
Chemistry and
Pharmacology:
2,5-Dimethoxy-4- (n)-propylthiophenethylamine
(2C-T-7), is a phenethylamine hallucinogen that is structurally
related to the schedule I phenethylamine hallucinogens,
4-bromo-2, 5-dimethoxyphenethylamine (2C-B, Nexus) and
mescaline. Based on structural similarly to these compounds, the
pharmacological profile of 2C-T-7 is expected to be
qualitatively similar to these hallucinogens.
Drug discrimination
studies in animals indicate that 2C-T-7 produces subjective
effects similar to those of several schedule I hallucinogens.
Subjective effects of 2C-T-7 were shown to be similar to
2,5-dimethoxy-4-methyl-amphetamine (DOM). In rats trained to
discriminate DOM, 2C-T-7 fully substituted for DOM and was
slightly less potent than 2C-B in eliciting DOM-like effects.
2C-T-7 was also shown to share some commonality with LSD; it
partially substituted for LSD up to doses that severely
disrupted performance in rats trained to discriminate LSD.
2C-T-7 can also function as a discriminative stimulus in rats.
Rats readily learned to discriminate 2C-T-7 from saline. When
either 2C-B or LSD was substituted for 2C-T-7, each elicited
2C-T-7-like discriminative stimulus effects.
The subjective effects of
2C-T-7, like those of 2C-B and DOM, appear to be mediated
through central serotonin receptors. 2C-T-7 selectively binds to
the 5-HT receptor system.
According to one published
case report, 2C-T-7 abuse has been associated with convulsions
in humans.
Illicit Uses:
2C-T-7 is abused orally
and intranasally for its hallucinogenic effects. Information
from a website about a variety of illicit drugs has suggested
that 2C-T-7 produce effects similar to those of 2C-B. This
information is based
on individuals self-administering 2C-T-7
illicitly and self-reporting the effects. Its effects include
visual hallucination, mood lifting, sense of well being,
emotionality, volatility,
increased appreciation of music, and psychedelic ideation. The
oral and intranasal doses recommended on this website are 10-50
mg and 5-10 mg, respectively. 2C-T-7’s onset and duration of
actions are dependent upon the route of administration.
Following oral administration, onset and duration of effects are
1 to 2.5 hours and 5 to 7 hours, respectively. After intranasal
administration, the onset of action and duration of effects are
5 to 15 minutes and 2 to 4 hours, respectively.
User Population:
Young adults are the main
abusers of 2C-T-7.
Illicit Distribution:
According to National
Forensic Laboratory Information System (NFLIS), since 2001,
state and local forensic laboratories analyzed 35 items of
2C-T-7 from 6 different law enforcement cases. According to
NFLIS, 2C-T-7 has been encountered in California, Florida,
Minnesota, Texas and Wisconsin.
One exhibit analyzed by
the Wisconsin State Crime Lab was shown be a mixture of 2C-T-7
and N,N-dipropyltryptamine (DPT). 2C-T-7 was being purchased
over the Internet from a company located in Indiana. This site
was traced to an individual who had been selling large
quantities of this substance since January 2000. Sales through
this Internet site were thought to be the major sources of
2C-T-7 in the United States. One clandestine laboratory was
identified in Las Vegas, Nevada as the supplier of 2C-T-7 to the
individual in Indiana. 2C-T-7 has been sold under the street
names Blue Mystic, T7, Beautiful, Tweety-Bird Mescaline or
Tripstay.
Control Status:
2C-T-7 was temporarily
placed into schedule I (CI) of the Controlled Substances Act
(CSA) on September 20, 2002 (67 FR 59163). On March 18, 2004,
the DEA published a Final Rule in the Federal Register
permanently placing 2C-T-7 in CI (69 FR 12794).
Comments and additional information are welcomed by the
Drug and Chemical Evaluation Section, FAX 202-353-1263 or
telephone 202-307-7183.
|